Brigitte N Sturm

List of Publications by Year
in descending order

25	932	471509 17	610901 24
papers	citations	h-index	g-index

25	25	25	3194
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	No changes in heme synthesis in human FriedreichÂ´s ataxia erythroid progenitor cells. Gene, 2017, 621, 5-11.	2.2	11
2	An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Journal of Neurology, 2015, 262, 1344-1353.	3.6	89
3	Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity. BioMetals, 2015, 28, 35-50.	4.1	3
4	Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD. Pharmaceutical Development and Technology, 2015, 20, 176-182.	2.4	6
5	White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin. Journal of Neuroimaging, 2014, 24, 504-508.	2.0	23
6	Variations of frataxin protein levels in normal individuals. Neurological Sciences, 2011, 32, 327-330.	1.9	13
7	Effects of Erythropoietin on Frataxin Levels and Mitochondrial Function in Friedreich Ataxia â€“ a Doseâ€“Response Trial. Cerebellum, 2011, 10, 763-769.	2.5	34
8	Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Movement Disorders, 2011, 26, 1935-1938.	3.9	33
9	A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Analytica Chimica Acta, 2010, 659, 129-132.	5.4	31
10	Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. European Journal of Clinical Investigation, 2010, 40, 561-565.	3.4	30
11	In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress. Arzneimittelforschung, 2010, 60, 459-465.	0.4	6
12	Review: Friedreich Ataxia and Erythropoietin. The Open Drug Discovery Journal, 2010, 2, 18-24.	0.7	0
13	Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial. Movement Disorders, 2008, 23, 1940-1944.	3.9	89
14	Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrology Dialysis Transplantation, 2007, 22, 2824-2830.	0.7	21
15	Hydrogen sulphide: A novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radical Research, 2007, 41, 741-747.	3.3	93
16	Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Annals of Neurology, 2007, 62, 521-524.	5.3	122
17	Differential response ofÂiron metabolism toÂoxidative stress generated byÂantimycin A andÂnitrofurantoin. Biochimie, 2006, 88, 575-581.	2.6	6
18	Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Analytical Biochemistry, 2005, 341, 241-250.	2.4	93

#	Article	IF	Citations
19	Intravenous iron preparations and ascorbic acid: Effects on chelatable and bioavailable iron. Kidney International, 2005, 67, 1161-1170.	5.2	23
20	Friedreich's Ataxia, No Changes in Mitochondrial Labile Iron in Human Lymphoblasts and Fibroblasts. Journal of Biological Chemistry, 2005, 280, 6701-6708.	3.4	68
21	Aluminum ions stimulate the oxidizability of low density lipoprotein by Fe2+: Implication in hemodialysis mediated atherogenic LDL modification. Free Radical Research, 2005, 39, 1225-1231.	3.3	6
22	Sulfite facilitates LDL lipid oxidation by transition metal ions: A pro-oxidant in wine?. FEBS Letters, 2005, 579, 6486-6492.	2.8	21
23	Nonâ€“Transferrin-Bound Iron in the Serum of Hemodialysis Patients Who Receive Ferric Saccharate. Journal of the American Society of Nephrology: JASN, 2004, 15, 1648-1655.	6.1	54
24	Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochemical Pharmacology, 2003, 65, 1973-1978.	4.4	31
25	Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. FEBS Journal, 2003, 270, 3731-3738.	0.2	26